Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents

CpG Drives Human Transitional B Cells to Terminal Differentiation and Production of Natural Antibodies

(2014) F. Capolunghi et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Inhibits Memory B Lymphocytes via Effects on Lymphoid Germinal Centers and Follicular Dendritic Cell Networks

(2014) J. H. Anolik et al.   JOURNAL OF IMMUNOLOGY

CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients

(2013) Jennifer Pieper et al.   BMC IMMUNOLOGY

Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression

(2013) Tomoyuki Yamaguchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Peripheral and Site-Specific CD4+CD28nullT Cells from Rheumatoid Arthritis Patients Show Distinct Characteristics

(2013) J. Pieper et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis

(2012) M. Bonelli et al.   ARTHRITIS AND RHEUMATISM

Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis

(2012) Zhuochun Huang et al.   CELLULAR IMMUNOLOGY

Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy

(2012) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

Combined Treatment of Etanercept and MTX Reverses Th1/Th2, Th17/Treg Imbalance in Patients with Rheumatoid Arthritis

(2011) Chen Lina et al.   JOURNAL OF CLINICAL IMMUNOLOGY

CTLA-4-Ig Therapy Diminishes the Frequency but Enhances the Function of Treg Cells in Patients with Rheumatoid Arthritis

(2011) Crisol Álvarez-Quiroga et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Baseline Numbers of Circulating CD28-negative T Cells May Predict Clinical Response to Abatacept in Patients with Rheumatoid Arthritis

(2011) MIRKO SCARSI et al.   JOURNAL OF RHEUMATOLOGY

Number and phenotype of rheumatoid arthritis patients’ CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept

(2011) Céline Blache et al.   RHEUMATOLOGY

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

(2008) M H Buch et al.   ANNALS OF THE RHEUMATIC DISEASES